Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Adoptive T-cell therapy for melanoma: Predictive biomarkers and potential for commercialization Radvanyi LG Miltenyi Biotec, Cologne, Germany February, 2013
2. Tumor-infiltrating lymphocyte therapy for melanoma and the search for biomarkers of response Radvanyi LG Ludwig Institute for Cancer Research (LICR), Lausanne, Switzerland February, 2013
3. TIL Therapy for Melanoma: Biomarkers, Costimulatory Molecules, and Other Interesting Things Radvanyi LG Melanoma Medical Oncology Lab Meeting, University of Texas M.D. Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX December, 2012
4. Adoptive T-cell Therapy for Melanoma: Trials and Tribulations in the Quest for FDA Approval Radvanyi LG Society of Immunotherapy for Cancer (SITC) 27th Annual Meeting, North Bethesda October, 2012
5. Tumor-infiltrating lymphocyte therapy for melanoma at MD Anderson: Clinical experience and search for biomarkers of response Radvanyi LG Global Academic Programs 2012 Conference, Oslo, Norway May, 2012
6. Tumor-infiltrating lymphocyte therapy for melanoma at MD Anderson: Clinical experience and search for biomarkers of response Radvanyi LG, Bernatchez C, Zhang M, Wu R, Haymaker C, and Hwu P Global Academic Programs 2012 Conference, Oslo, Norway May, 2012
7. Adoptive T-cell therapy for metastatic melanoma: From dream to reality Radvanyi LG XX Mexican Congress of Immunology, Merida, Mexico April, 2012
8. Higher TRPS-1 expression independently predicts better clinical outcome in ER+ breast cancer. Chen JQ, Xiao L, Litton J, Wu Y, Shen X, Zhang HZ, Katz RL, Sahin A, Warneke CL, Bondy M, Zhou R, Murray JL, and Radvanyi L 12th USCAP Meeting, March 17-23, 2012, Vancouver, BC, Canada March, 2012
9. Direct TCR Expression Analysis (DTEA) using nCounter™ technology to track TCR gene expression changes during T-cell adoptive therapy Radvanyi LG MD Anderson Symposium on Novel Approaches to Gene Expression, Gene Fusion, miRNA and CNV Analysis using the nCounter® Analysis System, Houston, TX February, 2012
10. Overview of Immunomonitoring Capabilities of MD Anderson IMCL for RTOG/BMS Study Radvanyi LG RTOG/BMS Immunotherapy Monitoring Consensus Meeting, Atlanta, GA January, 2012
11. Direct TCR Expression Assay (DTEA) for quantifying T-cell Receptor α-chain and β-chain Diversity using the Digital nCounter Assay System and its Implications in T cell Adoptive Therapy Maiti S, Zhang M, Bernatchez C, Torikai H, Huls H, Lee DA, Hwu P, Radvanyi L, Cooper LJN. Society for the Immunotherapy of Cancer (SITC) 26th Annual Meeting, Bethesda MD November, 2011
12. Improving melanoma tumor-infiltrating lymphocyte phenotype and function for adoptive cell therapy through the TNFR super family member 4-1BB Chacon JA, Wu RC, Wang Z, Ma W, Gao Yi, Davis R Eric, Hwu P, and Radvanyi LG Society for the Immunotherapy of Cancer (SITC) 26th Annual Meeting, Bethesda MD November, 2011
13. T-Cell Therapy Radvanyi LG Melanoma at MD Anderson Cancer Center, Presentation to the Board of the Melanoma Research Alliance, Houston, TX November, 2011
14. New Immunoregulatory Pathways Revealed by Studying IL-2 Therapy and Adoptive Cell Therapy Using Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients Radvanyi LG Kyoto University Global COE “Center for Frontier Medicine” International Symposium/Retreat, Kobe, Japan September, 2011
15. Update on Melanoma TIL Adoptive Cell Therapy Program Radvanyi LG MD Anderson Melanoma Multidisciplinary Dinner, Houston, TX September, 2011
16. Clinical responses to ipilimumab plus temozolomide in metastatic melanoma Patel SP, Bedikian AY, Papadopoulos NE, Hwu WJ, Kim KB, Homsi J, Davies MA, Radvanyi LG, Woodard K, Mahoney SL, Hwu P. ASCO Annual Meeting, June 3-7, 2011, Chicago, IL June, 2011
17. Costimulation through 4-1BB/CD137 improves the expansion and function of CD8+ melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy J. Chacon, Yijun Wang, Richard Wu, Patrick Hwu, and Laszlo Radvanyi. American Association of Immunology (AAI) Annual Meeting, May 13-17, 2011, San Francisco, CA May, 2011
18. Melanoma, T-regulatory cells, ICOS, and IL-2 therapy: What’s the connection? Radvanyi LG Cancer Immunotherapy and Immunomonitoring (CITIM), Budapest, Hungary May, 2011
19. BTLA mediates enhanced survival of CD8+ tumor-infiltrating lymphocytes and a positive clinical response during adoptive cell therapy for melanoma. Radvanyi L, Bernatchez C, Wu R, Zhang M, Hwu P Keystone Symposia: Immunregulatory Networks. April 1-6, 2011, Breckenridge, CO. April, 2011
20. Unleashing the power of the immune system against metastatic melanoma Radvanyi LG MD Anderson Division of Cancer Medicine Grand Rounds, Houston, TX April, 2011
21. Unleashing the power of the immune system against metastatic melanoma Radvanyi LG National Institute of Oncology of Hungary, Budapest, Hungary April, 2011
22. Update on Adoptive T Cell Therapy Clinical Trials at MD Anderson Cancer Center Radvanyi LG Dr. Miriam and Sheldon Adelson Medical Research Foundation (AMRF) Meeting, Las Vegas, NV February, 2011
23. Discovery and development of biomarkers to select melanoma patients for high-dose IL-2 therapy Radvanyi LG Prometheus Therapeutics & Diagnostics, San Diego, CA February, 2011
24. Unleashing the power of the immune system against metastatic melanoma Radvanyi LG St. Michael’s Hospital, Medical Grand Rounds, Toronto, Canada February, 2011
25. Manipulating T-cell costimulation to improve adoptive T-cell therapy for metastatic melanoma (Plenary Speaker) Radvanyi LG Melanoma Research Alliance (MRA) Third Annual Scientific Retreat, Washington, DC February, 2011
26. T cell suppressive mechanisms in cancer and implications for inflammatory and triple-negative breast cancer Radvanyi LG MD Anderson Inflammatory Breast Cancer Group Talk, Houston, TX January, 2011
27. Quantitative Immunohistochemical analysis and prognositc significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Sahin A, Katz R, Murray JL, Radvanyi L San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX December, 2010
28. TRPS-1, a new GATA family transcription factor, regulates epithelial-mesenchymal transition and maintains an estrogen responsive, Claudin-positive phenotype in breast cancer cells Bao Y, Chen JQ, Wu Y, Leng XH, Wang E, Marincola F, Radvanyi LG. San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX December, 2010
29. Adoptive T-cell therapy for metastatic melanoma: the M.D. Anderson experience Radvanyi LG ISBTC 25th Annual Meeting, Washington, DC October, 2010
30. New diagnostic and prognostic markers for hormonal cancer risk Radvanyi LG Sixth International Symposium on Hormonal Oncogenesis (ISHO), Japan September, 2010
31. New insights on the modulation of epithelial-mesenchymal transition in breast cancer by a new GATA family transcription factor Radvanyi LG Sixth International Symposium on Hormonal Carcinogenesis, Tokyo, Japan September, 2010
32. New biomarkers predicting positive clinical responses to high-dose IL-2 therapy in metastatic melanoma patients Radvanyi LG Melanoma Grand Rounds, University of Texas M.D. Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX July, 2010
33. Adoptive transfer of therapy using expanded melanoma –specific T cells programmed ex vivo for improved efficacy. Andersson HA, Hernandez JA, Maiti S, Huls H, Radvanyi LG, Cooper L. American Society for Blood Marrow Transplantation, 2011 BMT Tandem Meetings, Honolulu, HI February, 2010
34. Digital Multiplexed Quantification of both T-cell Receptor β-chain and α-chain Diversity in T cells using the Nanostring nCounter Assay System Maiti S, Zhang M, Bernatchez C, Torikai H, Kellar D, Gibbons H, Hernandez J, Andersson H, Huls H, Lee DA, Hwu P, Radvanyi LG, Cooper LJN American Society for Blood Marrow Transplantation, 2011 BMT Tandem Meetings, Honolulu, HI February, 2010
35. New biomarkers predicting positive clinical responses to high-dose IL-2 therapy in metastatic melanoma patients Radvanyi LG M.D. Anderson Melanoma & Skin Cancer Seminar Series, University of Texas M.D. Anderson Cancer Center, Houston, TX February, 2010
36. Identification of a novel CD8+CD57+ T-cell subset in human melanoma exhibiting an incompletely differentiated CTL phenotype (oral platform presentation). Wu R, Liu S, Li Y, Hwu P, Lizee G, Radvanyi LG International Society for the Biological Therapy of Cancer (ISBTC), 24th Annual Meeting, Washington D.C October, 2009
37. T-cell therapy of melanoma Radvanyi LG M.D. Anderson melanoma & Skin Cancer Seminar Series, University of Texas M.D. Anderson Cancer Center, Houston, TX October, 2009
38. Improving tumor infiltrating lymphocyte survival and function for melanoma adoptive T-cell therapy through 4-1BB costimulation Hernandez JA, Li Y, Wang Y, Wu R, Hwu P, Radvanyi L. International Society for the Biological Therapy of Cancer (ISBTC), 24th Annual Meeting, Washington D.C October, 2009
39. IL-15 is superior to IL-2 in supporting antigen-specific expansion and maintenance of T-cell memory in melanoma CD8+ tumor-infiltrating lymphocytes Li Y, Hernandez JA, Wu R, Hwu P, Radvanyi P International Society for the Biological Therapy of Cancer (ISBTC), 24th Annual Meeting, Washington D.C. October, 2009
40. Update on current status and analysis of TIL growth in the 2004-0069 adoptive T-cell clinical trial for melanoma Radvanyi LG Presentation given to Dr. Ray Dubois (Provost of MDACC), University of Texas M.D. Anderson Cancer Center, Houston, TX September, 2009
41. Vaccination against breast cancer: Why bother and what new antigens can we target?, Radvanyi LG Breast Cancer Clinical Research Program (BCCR) monthly lecture series, University of Texas M.D. Anderson Cancer Center, Department of Breast Medical Oncology, Houston, TX May, 2009
42. Leukapheresis of melanoma patients: The Why's, the What's and the How's Radvanyi LG Melanoma Grand Rounds, University of Texas M.D. Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX April, 2009
43. TRPS-1 in breast cancer Chen, J.Q., Litton, J.K., Warneke, C.L., Zhang, H., Berinstein, N., Sahin, A.A., Bondy, M.L., Hortobagyi, G.N., Murray, J.L., Radvanyi, L AACR Annual Meeting, Colorado Convention Center, Denver, CO April, 2009
44. Estrogen drives early breast preneoplasia via selective/specific protein and RNA overexpression in female ACI rats Li SA, Hong Y, Radvanyi L, Chen JQ, Li JJ. AACR annual Meeting, Colorado Convention Center, Denver, CO April, 2009
45. Update on current status and analysis of TIL growth in the 2004-0069 adoptive T-cell clinical trial for melanoma Radvanyi LG Melanoma Grand Rounds, University of Texas M.D. Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX February, 2009
46. Clinical status and previous treatment of melanoma patients influence the expansion of TIL for adoptive T cell therapy Peddareddigari V, Miller PW, Bekele NB, Overwijk WW, Ross MI, Lee JE, Gershenwald JE, Prieto VG, Hwu P, Radvanyi L. ASCO Annual Meeting, Orlando, FL January, 2009
47. Tumor-Infiltrating lymphocytes: Clinical and biological perspectives Radvanyi LG Center for Cancer Immunology Researach 5th Annual Retreat, Center for Cancer Immunology Research (CCIR), The Woodlands, TX November, 2008
48. Rapid expansion of melanoma TIL for adoptive cell therapy leads to loss of CD28 and reduced proliferative potential in the MART-1-specific T cell population. Li Y, Liu S, Hernandez J, Hwu P, Radvanyi LG International Society for the Biological Therapy of Cancer,23rd Annual Meeting October, 2008
49. Adoptive T-cell (TIL) therapy for melanoma at the MD Anderson Cancer Center: Early results indicate a promising future Radvanyi LG, Peddareddigari V, Bushnell K, Bassie R, Fulbright O.J., Gonzalez M, Miller P, Hwu W, Kim K, Bedikian A, Papadopoulos N, McMannis JD, Shpall E, Ross M, Lee J, Gershenwald J, Mansfield P, Lucci A, Cormier J, Prieto V, Hwu P. International Society for the Biological Therapy of Cancer, 23rd Annual Meeting October, 2008
50. Maintenance of tumor antigen-specific cytolytic T cells during expansion of TIL for adoptive immunotherapy Liu S, Etto T, Sukhumalchandra P, Rodriguez-Cruz T, Li Y, Molldrem J, Hwu P, Radvanyi LG, Lizee G. International Society for the Biological Therapy of Cancer, 23rd Annual Meeting October, 2008
51. TRPS-1 in breast cancer Litton, J.K., Chen, J.Q., Warneke, C.L., Zhang, H., Berinstein, N., Sahin, A.A., Bondy, M.L., Bortobagyi, G.N., Murray, J.L., Radvanyi,L Breast Cancer Symposium: Integrating Emerging Science into Clinical Practice, Washington, DC September, 2008
52. Adoptive T-cell therapy for melanoma and other solid cancers: Where are we and where are we going? Radvanyi LG University of British Columbia, Deeley Research Center, BC Cancer Agency, Victoria, Canada July, 2008
53. "TRPS-1: A new immunological and molecular target in breast cancer Radvanyi LG Sanofi Pasteur, Toronto, Canada May, 2008
54. New epitopes to improve peptide vaccination against the tumor-asociated antigen survivin Bernatchez, C, Li, Y., Vina-Fernandez, M, Cano, M, Chang, DZ, Radvanyi LG. American Association of Immunologists(AAI) Annual Meeting April, 2008
55. Immunological and molecular markers predicting high-dose IL-2 therapy clinical response in metastatic melanoma patients Radvanyi LG Melanoma Faculty Meeting, University of Texas M.D. Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX January, 2008
56. Interaction between TGF-beta and beta-catenin signaling:A novel pathway regulating CTL differentiation in cancer Radvanyi LG Melanoma Medical Oncology Lab Meeting, University of Texas M.D. Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX January, 2008
57. Update on MD Anderson Melanoma Adoptive TIL Therapy Clinical Trial Radvanyi LG Melanoma Translational Objectives Meeting, University of Texas, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX November, 2007
58. Discovery and validatin of new immunotherapy targets for breast cancer Radvanyi LG Veterinary Sciences Seminar, University of Texas M.D. Anderson Cancer Center, Department of Veterinary Sciences, Houston, TX September, 2007
59. Barking up the wrong tree: Are we targeting the wrong tumor antigen peptides to the wrong HLA?, Radvanyi LG Melanoma Medical Oncology Lab Meeting, University of Texas M.D. Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX March, 2007
60. Joint Journal Club Radvanyi LG University of Texas M.D. Anderson Cancer Center, Melanoma Medical Oncology/ Lymphoma Myeloma, Houston, TX March, 2007
61. Discovery and validation of new immunotherapy targets for breast cancer Radvanyi LG UT MD Anderson Cancer Center Breast Medical Oncology Noon-time Conference, UT MD Anderson Cancer Center, Breast Medical Oncology, Houston, TX January, 2007
62. Molecular and Immunological Mechanisms of High-dose Anti-tumor Activitiy in Patients with Metastatic Melanoma Radvanyi LG Melanoma Translational Objectives Meeting, University of Texas, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX December, 2006
63. CORE B: Immune Monitoring Core Radvanyi LG Center for Cancer Immunology Retreat, University of Texas, MD Anderson Cancer Center, Immunology, Galveston, TX November, 2006
64. Towards More Rational Vaccines and Immunotherapies for Human Melanoma Radvanyi LG 2nd International Congress of Basic and Clinical Immunogenomics, Budapest, Hungary October, 2006
65. Maintenance of CD27+ Effector memory T Cells During ex vivo Expansion of Melanoma TIL is Critical for Adoptive T-cell Therapy Li Y, Liu S, Campbell R, Lizee G, Hwu P, Radvanyi R International Society for the Biological Therapy of Cancer, 21st Annual Meeting October, 2006
66. New Immune Monitoring Core laboratory at the MD Anderson South Campus Radvanyi LG Baylor College of Medicine and The University of Texas M.D. Anderson Cancer Center Research Symposium, Baylor College of Medicine and University of Texas, MD Anderson Cancer Center, Houston, TX July, 2006
67. State of Tumor-infiltrating T-cell differentiation in human melanomas and its potential impact on adoptive T-cell therapy Radvanyi LG Melanoma Medical Oncology Lab Meeting, University of Texas, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX July, 2006
68. NHLBI PO1 Grant Project #3 Presentation Radvanyi LG CCIR Program Project Grant Meeting, University of Texas, MD Anderson Cancer Center, Immunology, Houston, TX June, 2006
69. Molecular and Immunological Mechanisms of High-Dose IL-2 Antitumor Activity in Patients with Metastatic Melanoma Radvanyi LG Novartis oncology IL-2 Investigators Meeting, ASCO 2006, Atlanta, GA June, 2006
70. CCIR Journal Club, CCIR Journal Club Radvanyi LG University of Texas, MD Anderson Cancer Center, Immunology, Houston, TX March, 2006
71. Phenotypic analysis of Fresh and Cultured Melanoma Tumor-Infiltrating Leukocytes Radvanyi LG Melanoma Medical Oncology Lab Meeting, University of Texas, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX February, 2006
72. Journal Club Radvanyi LG Melanoma/Lyphoma Joint Journal Club Meeting, University of Texas, MD Anderson Cancer Center, Melanoma Medical Oncology and Lymphoma/Myeloma, Houston, TX January, 2006
73. Phenotypic Analysis of Effector and Regulatory T Lymphocytes Derived from Fresh Human melanomas Lui, S, Li, Y, Liakou, C, Hwu, P, Lizee, G, Radvanyi, L. Tumor Immunology, Special meeting of AACR January, 2006
74. Adoptive T cell (TIL) Therapy with Dendritic Cell Co-vaccination for Metastatic Melanoma: New findings and Methods on TIL and Dendritic Cell Generatino Radvanyi LG Melanoma Translational Objectives Meeting, University of Texas, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX December, 2005
75. New Antigen Targets for Active Immunotherapy Against Breast Cancer Radvanyi LG Center for Cancer Immunology Retreat, University of Texas, MD Anderson Cancer Center, Immunology, Galveston, TX November, 2005
76. Molecular and Immunological Correlates for IL-2 Responsiveness in Melanoma Patients Radvanyi LG Chiron medical Advisory Board Meeting: Biomarkers for Proleukin Therapy in Melanoma, Chiron, Houston, TX November, 2005
77. TIL Lab Updates Radvanyi LG Melanoma Medical Oncology Lab Meeting, University of Texas, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX October, 2005
78. Improved Approaches for Vaccination Against Breast Cancer Radvanyi LG Clinical Translational Immunology Seminar Series, University of Texas, MD Anderson Cancer Center, Houston, TX September, 2005
79. TIL Lab Updates Radvanyi LG Melanoma Medical oncology Lab Meeting, University of Texas, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX April, 2005
80. Low dose type I IFN boosts cell-mediated immune responses to an attenuated canarypox viral vaccine Radvanyi L, Hakimi J, Karunakaren L, Dunn P NA March, 2005
81. Canarypox (ALVAC) Vaccines for Melanoma Immunotherapy: Results of Basic Science and Clinical Studies Radvanyi LG Melanoma Translational Objectives Meeting, University of Texas, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX February, 2005
82. New tumor-specific targets for breast cancer and immune monitoring tools for vaccine clinical trials Radvanyi LG Bone Marrow Transplantation Lab Meeting, University of Texas, MD Anderson Cancer Center, BMT, Houston, TX January, 2005
83. Therapeutic Cancer Vaccines: A New Challenge for the Vaccine Industry Radvanyi LG 6th CAnadian Immunization Conference, Palais Des Congres de Montreal, Montreal, Quebec, Canada December, 2004
84. Discovery and Validation of New Vaccine Targets for Cancer: Combining the Power of Genomics, Bioinformatics and Immunology Radvanyi LG 1st International Congress of BAsic and Clinical Immunogenomics, Budapest, Hungary October, 2004
85. New antigens for therapeutic vaccines against breast cancer Radvanyi LG CHI Conference on Cancer Immunotherapeutics, Boston, MA September, 2004
86. Responses of human cells to Canarypox virus infection: Implications for antigen presentation during vaccination, Biotecnologia Habana 2003: Medical applications of Biotechnology Radvanyi LG Center for Genetic Engineering and Biotechnology, Havana, Cuba November, 2003
87. Discovery and Immunological Characterization of BFA4/TRPS-1: A new overexpressed Gene in Breast Cancer Radvanyi LG 18th Annual meeting of the International Society for the Bilogical Therapy of Cancer (iSBTc), Bethesda, MD October, 2003
88. Prospects for an antigen-specific vaccine approach against breast cancer and tumor angiogenesis Radvanyi LG McGill Cancer Center, McGill University, Montreal Quebec, Canada April, 2003
89. New antigens and vectors for vaccination against breast cancer and tumor angiogenesis Radvanyi LG 6th Latin American Immunology congress, Havana, Cuba December, 2002
90. New antigens and vectors for therapeurtic immunization against cancer Radvanyi LG 15th Mexican Congress of Immunology, Ixtapa, Mexico April, 2002



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Adoptive T-cell Therapy for Melanoma: The Road to Commercialization 4th Cancer Targets and Therapeutics February, 2013

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.